A VLP-based vaccine targeting domain III of the West Nile virus e protein protects from lethal infection in mice

Virology Journal

Volumn 7, Issue , 2010, Pages

  Spohn, Gunther ^a   Jennings, Gary T ^a   Martina, Byron Ee ^b   Keller, Iris ^a,d   Beck, Markus ^a,e   Pumpens, Paul ^c   Osterhaus, Albert Dme ^b   Bachmann, Martin F ^a  

^a CYTOS BIOTECHNOLOGY AG   (Switzerland)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c LATVIAN BIOMEDICAL RESEARCH AND STUDY CENTRE   (Latvia)

^d AO FOUNDATION   (Switzerland)

^e ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; WEST NILE VACCINE; VACCINE; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIOPHAGE; CONTROLLED STUDY; DRUG TARGETING; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; TRANSMISSION ELECTRON MICROSCOPY; VACCINE PRODUCTION; WEST NILE FEVER; WEST NILE FLAVIVIRUS; ANIMAL; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; MORTALITY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

ANIMALIA; MUS; WEST NILE VIRUS;

ANIMALS; BACTERIOPHAGES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; PROTEIN STRUCTURE, TERTIARY; VACCINES, CONJUGATE; VIRAL ENVELOPE PROTEINS; WEST NILE FEVER; WEST NILE VIRUS; WEST NILE VIRUS VACCINES;

EID: 77954194472     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-146     Document Type: Article

References (40)

1. West Nile virus. GL Campbell AA Marfin RS Lanciotti DJ Gubler, Lancet Infect Dis 2002 2 519 529 10.1016/S1473-3099(02)00368-7 12206968
2. Virology, pathology, and clinical manifestations of West Nile virus disease. EB Hayes JJ Sejvar SR Zaki RS Lanciotti AV Bode GL Campbell, Emerg Infect Dis 2005 11 1174 1179 16102303
3. CCR5 deficiency increases risk of symptomatic West Nile virus infection. WG Glass DH McDermott JK Lim S Lekhong SF Yu WA Frank J Pape RC Cheshier PM Murphy, J Exp Med 2006 203 35 40 10.1084/jem.20051970 16418398
4. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. JK Lim CY Louie C Glaser C Jean B Johnson H Johnson DH McDermott PM Murphy, J Infect Dis 2008 197 262 265 10.1086/524691 18179388
5. The epidemic of West Nile virus in the United States, 2002. DR O'Leary AA Marfin SP Montgomery AM Kipp JA Lehman BJ Biggerstaff VL Elko PD Collins JE Jones GL Campbell, Vector Borne Zoonotic Dis 2004 4 61 70 10.1089/ 153036604773083004 15018774
6. The continuing spread of West Nile virus in the western hemisphere. DJ Gubler, Clin Infect Dis 2007 45 1039 1046 10.1086/521911 17879923
7. West Nile virus in Spain: report of the first diagnosed case (in Spain) in a human with aseptic meningitis. D Kaptoul PF Viladrich C Domingo J Niubo S Martinez-Yelamos F De Ory A Tenorio, Scand J Infect Dis 2007 39 70 71 10.1080/00365540600740553 17366016
8. First human case of West Nile virus neuroinvasive infection in Italy, September 2008 - case report. G Rossini F Cavrini A Pierro P Macini A Finarelli C Po G Peroni A Di Caro M Capobianchi L Nicoletti, et al. Euro Surveill 2008 13 18926106
9. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Arroyo C Miller J Catalan GA Myers MS Ratterree DW Trent TP Monath, J Virol 2004 78 12497 12507 10.1128/JVI.78.22.12497-12507.2004 15507637
10. A live, attenuated recombinant West Nile virus vaccine. TP Monath J Liu N Kanesa-Thasan GA Myers R Nichols A Deary K McCarthy C Johnson T Ermak S Shin, et al. Proc Natl Acad Sci USA 2006 103 6694 6699 10.1073/pnas.0601932103 16617103
11. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. B Guy F Guirakhoo V Barban S Higgs TP Monath J Lang, Vaccine 28 632 649 10.1016/j.vaccine.2009.09. 098 19808029
12. Antigenic structure of flavivirus proteins. JT Roehrig, Adv Virus Res 2003 59 141 175 full-text 14696329
13. Quantifying the specific binding between West Nile virus envelope domain III protein and the cellular receptor alphaVbeta3 integrin. JW Lee JJ Chu ML Ng, J Biol Chem 2006 281 1352 1360 10.1074/jbc.M506614200 16275649
14. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. DW Beasley AD Barrett, J Virol 2002 76 13097 13100 10.1128/JVI.76.24.13097-13100.2002 12438639
15. Solution structure and antibody binding studies of the envelope protein domain III from the New York strain of West Nile virus. DE Volk DW Beasley DA Kallick MR Holbrook AD Barrett DG Gorenstein, J Biol Chem 2004 279 38755 38761 10.1074/jbc.M402385200 15190071
16. Structural basis of West Nile virus neutralization by a therapeutic antibody. GE Nybakken T Oliphant S Johnson S Burke MS Diamond DH Fremont, Nature 2005 437 764 769 10.1038/nature03956 16193056
17. The DE loop of the domain III of the envelope protein appears to be associated with West Nile virus neutralization. KS Choi JJ Nah YJ Ko YJ Kim YS Joo, Virus res 2007 123 216 218 10.1016/j.virusres.2006.09.002 17027114
18. Characterization of neutralizing antibodies to West Nile virus. MD Sanchez TC Pierson D McAllister SL Hanna BA Puffer LE Valentine MM Murtadha JA Hoxie RW Doms, Virology 2005 336 70 82 10.1016/j.virol.2005.02.020 15866072
19. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. T Oliphant M Engle GE Nybakken C Doane S Johnson L Huang S Gorlatov E Mehlhop A Marri KM Chung, et al. Nat Medicine 2005 11 522 530 10.1038/nm1240 (Pubitemid 40685975)
20. Immunization of mice against West Nile virus with recombinant envelope protein. T Wang JF Anderson LA Magnarelli SJ Wong RA Koski E Fikrig, J Immunol 2001 167 5273 5277 11673542 (Pubitemid 33009765)
21. Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus. BE Martina P Koraka P van den Doel G van Amerongen GF Rimmelzwaan AD Osterhaus, Vaccine 2008 26 153 157 10.1016/j.vaccine.2007.10.055 18069096
22. A recombinant envelope protein vaccine against West Nile virus. M Ledizet K Kar HG Foellmer T Wang SL Bushmich JF Anderson E Fikrig RA Koski, Vaccine 2005 23 3915 3924 10.1016/j.vaccine.2005.03.006 15917113
23. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. JH Chu CC Chiang ML Ng, J Immunol 2007 178 2699 2705 17312111
24. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. WF McDonald JW Huleatt HG Foellmer D Hewitt J Tang P Desai A Price A Jacobs VN Takahashi Y Huang, et al. J Infect Dis 2007 195 1607 1617 10.1086/517613 17471430
25. A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. G Spohn R Guler P Johansen I Keller M Jacobs M Beck F Rohner M Bauer K Dietmeier TM Kundig, et al. J Immunol 2007 178 7450 7457 17513796
26. Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. G Spohn I Keller M Beck P Grest GT Jennings MF Bachmann, Eur J Immunol 2008 38 877 887 10.1002/eji.200737989 18253928
27. Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. G Spohn K Schwarz P Maurer H Illges N Rajasekaran Y Choi GT Jennings MF Bachmann, J Immunol 2005 175 6211 6218 16237119
28. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. TA Rohn GT Jennings M Hernandez P Grest M Beck Y Zou M Kopf MF Bachmann, Eur J Immunol 2006 36 2857 2867 10.1002/eji.200636658 17048275
29. Nucleotide sequence of a ssRNA phage from Acinetobacter: kinship to coliphages. J Klovins GP Overbeek SH van den Worm HW Ackermann J van Duin, J Gen Virol 2002 83 1523 1533 12029168
30. Cryo electron microscopy reconstructions of the Leviviridae unveil the densest icosahedral RNA packing possible. SH van den Worm RI Koning HJ Warmenhoven HK Koerten J van Duin, J Mol Biol 2006 363 858 865 10.1016/j.jmb.2006.08.053 16989861
31. Recombinant RNA phage Q beta capsid particles synthesized and self-assembled in Escherichia coli. TM Kozlovska I Cielens D Dreilinna A Dislers V Baumanis V Ose P Pumpens, Gene 1993 137 133 137 10.1016/0378-1119(93)90261-Z 7506687 (Pubitemid 24053742)
32. Translational repression by bacteriophage MS2 coat protein expressed from a plasmid. A system for genetic analysis of a protein-RNA interaction. DS Peabody, J Biol Chem 1990 265 5684 5689 2108146
33. Versatile Virus-Like Particle Carrier for Epitope Based Vaccines. AC Tissot R Renhofa N Schmitz I Cielens E Meijerink V Ose GT Jennings P Saudan P Pumpens MF Bachmann, PLOS One 2010 5 3 9809 10.1371/journal.pone.0009809 20352110
34. A recombinant influenza A expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus. BEE Martina P van den Doel P Koraka G van Amerongen G Spohn BL Haagmans RAM Fouchier ADME Osterhaus GF Rimmelzwaan, PLOS One
35. Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus. CY Huang SJ Silengo MC Whiteman RM Kinney, J Virol 2005 79 7300 7310 10.1128/JVI.79.12.7300-7310.2005 15919884
36. The structural immunology of antibody protection against West Nile virus. MS Diamond TC Pierson DH Fremont, Immunol rev 2008 225 212 225 10.1111/j.1600-065X.2008.00676.x 18837784
37. The influence of antigen organization on B cell responsiveness. MF Bachmann UH Rohrer TM Kundig K Burki H Hengartner RM Zinkernagel, Science 1993 262 1448 1451 10.1126/science.8248784 8248784
38. Exploiting viral properties for the rational design of modern vaccines. G Spohn MF Bachmann, Expert Rev Vaccines 2008 7 43 54 10.1586/14760584.7.1.43 18251693
39. The coming of age of virus-like particle vaccines. GT Jennings MF Bachmann, Biol Chem 2008 389 521 536 10.1515/BC.2008.064 18953718
40. WO2007/039552 A1: Interleukin-1 conjugates and uses thereof. MF Bachmann G Spohn, 2007